Michael joined Brandon Capital in 2016.
Prior to joining Brandon Capital, Michael served as Senior Business Development Manager at Monash University, managing the Life Sciences portfolio for the Faculty of Medicine. In this role, he led multiple opportunities that became collaborations and partnered assets with global pharmaceutical companies and emerging biotechnology companies.
Earlier in his career, Michael was an Investment Manager (Life Sciences) at TTCF, a seed and venture commercialisation fund supporting academic research-driven innovation. He led a number of life sciences transactions, including Nexvet Biopharma (NASDAQ: NVET), which was acquired by Zoetis in 2017 for its lead monoclonal antibody asset, now marketed as Solensia.
Michael completed a Roche Research Foundation Postdoctoral Fellowship at ISREC (EPFL) in Lausanne, Switzerland. He holds a Bachelor of Science (First-Class Honours) and a PhD in stem cell biology from the University of Adelaide, as well as an MBA in Technology Management from La Trobe University. He is also a graduate of the Australian Institute of Company Directors.
Since joining Brandon Capital, Michael has led investments and company formation across a range of therapeutic areas and modalities, including AdvanCell Isotopes (oncology/radioligand therapy), Cincera Therapeutics (fibrotic diseases/small molecule), Currus Biologics (oncology/biologics and cell therapy), Foray Therapeutics (ocular pain/small molecule), Mirugen (retinal disease/gene therapy) and xCystence Bio (kidney disease/targeted protein degradation). He currently serves as a Non-Executive Director of Cincera, Currus, Foray, Mirugen and a stealth-stage company (autoimmune/small molecule), as well as a Board Observer at xCystence. He works closely with management teams and co-investors on company strategy, financing, business development and partnering.
Michael also previously led Brandon Capital’s CUREator program and was closely involved in securing A$33 million in grant funding to support Australian biomedical innovation.
